Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. Materials and Methods: We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively. Results: A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. Conclusion: Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, K., Caldarola, G., Pinto, L. M., Girolomoni, G., Marangoni, F., Bellinato, F., Gisondi, P., Scandagli, I., Prignano, F., Pimpinelli, N., Tomasini, C., Barruscotti, S., Desimoni, E., Simonetti, O., Ambrogio, F., Foti, C., Boccaletti, V., Fraghi, A., Marzano, A. V., Mattioli, M. A., Rocca, L., Barbareschi, M., Ferrucci, S. M., Gallo, G., Ribero, S., Quaglino, P., Balestri, R., Ioris, T., Caposienacaro, R. D., Zalaudek, I., Vagnozzi, E., Fargnoli, M. C., Caponio, C., Rubegni, P., Cinotti, E., Trovato, E., Romanelli, M., Dini, V., Manzomargiotta, F., Feliciani, C., De Felicidelgiudice, M. B., Atzori, L., Sanna, S., Lembo, S., Raimondo, A., Magnano, M., Starace, M., Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study, <<JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY>>, 2024; (2024): N/A-N/A. [doi:10.1111/jdv.20312] [https://hdl.handle.net/10807/299918]
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study
Peris, Ketty;Caldarola, Giacomo;Pinto, Lorenzo Maria;Rocca, Lorenzo;Zalaudek, Iris;Fargnoli, Maria Concetta;Romanelli, Margherita;Dini, Veronica;
2024
Abstract
Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. Materials and Methods: We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively. Results: A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. Conclusion: Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
